Drug Interaction Report

Amitriptyline and Desvenlafaxine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Amitriptyline

Elavil
+

Desvenlafaxine

Pristiq
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 525 documented Amitriptyline interactions, 421 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Effects may be stronger
The Bottom Line
Taking amitriptyline with desvenlafaxine can raise amitriptyline levels and increase the risk of serotonin syndrome, so watch for symptoms like fever, fast heartbeat, and confusion. Your care team can manage this by tailoring your dose and monitoring you closely, so keep both as prescribed and report any warning signs.

Both amitriptyline (Elavil) and desvenlafaxine (Pristiq) raise serotonin, a brain chemical that affects mood. Using them together can push serotonin too high, which in rare cases causes a serious reaction called serotonin syndrome. Warning signs include a fast heartbeat, high blood pressure, fever, sweating, shakiness or muscle twitching, agitation, or confusion.

On top of that, desvenlafaxine can slow down how your body breaks amitriptyline down, so more of it may build up. The good news is that your care team knows how to handle this. They can tailor your doses and watch you closely, especially when starting or increasing either medicine. Keep taking both as prescribed and let your doctor or pharmacist know right away if you feel any of those symptoms.

Effect: Additive serotonergic activity plus increased amitriptyline exposure. Desvenlafaxine is a weak CYP2D6 inhibitor and reduces metabolism of amitriptyline (a CYP2D6 substrate), raising its levels; both drugs are serotonergic, increasing serotonin syndrome risk.

  • Direction: Increased amitriptyline exposure and additive serotonergic PD effect.
  • Severity/evidence: Major; probable. Onset unspecified.
  • Management: No dose change needed with desvenlafaxine 100 mg/day or less. Reduce the CYP2D6 substrate dose by 50% with desvenlafaxine 400 mg/day (unapproved); restore original dose if that dose is stopped.
  • Monitor: Serotonin syndrome signs (autonomic instability, hyperthermia, hyperreflexia, mental status changes), especially at initiation/titration. Discontinue both and give supportive care if it develops.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Increased CYP2D6 substrate exposure and an increased risk of serotonin syndrome (hypertension, tachycardia, hyperthermia, myoclonus, mental status changes)

Interaction Deep Dive

When desvenlafaxine, which acts as both a serotonergic drug and a weak CYP2D6 inhibitor, is given together with another serotonergic agent that also serves as a CYP2D6 substrate, the result can be greater drug exposure along with a heightened risk of serotonin syndrome. This condition can be life-threatening. Its presentation may involve altered mental status (for example, agitation, hallucinations, coma), autonomic instability (for example, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (for example, hyperreflexia, incoordination), and gastrointestinal manifestations (for example, nausea, vomiting, diarrhea). Should serotonin syndrome occur, both drugs should be stopped and supportive symptomatic care begun. When these agents must be used together, the CYP2D6 substrate requires no dose modification alongside desvenlafaxine at 100 mg/day or lower. When desvenlafaxine 400 mg/day (an unapproved dose) is used concurrently, cut the CYP2D6 substrate dose in half, and return the CYP2D6 substrate to its original dose if concurrent desvenlafaxine 400 mg/day is stopped. Every patient should be watched carefully for signs and symptoms of serotonin syndrome, particularly when either medication is being started or its dose raised1.

Why it happens (mechanism)

Inhibition of CYP2D6-mediated metabolism by desvenlafaxine; additive serotonergic effects

How to manage this interaction

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed with the right dosing and monitoring.

  • At usual desvenlafaxine doses (100 mg/day or less), amitriptyline typically does not need a dose change.
  • At very high desvenlafaxine doses, your team may lower the amitriptyline dose and restore it later; they will individualize this.
  • Your care team may monitor you more closely, especially when starting either drug or raising a dose.

Get urgent help if you notice fast heartbeat, fever, sweating, muscle twitching, shivering, agitation, or confusion, and ask your pharmacist or doctor before making any changes.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) In a clinical study, giving desipramine (a CYP2D6 substrate) 50 mg together with desvenlafaxine 400 mg/day (an unapproved dose) produced an increase of about 50% in the Cmax and 90% in the AUC of desipramine. The changes in desipramine metabolism were not regarded as clinically relevant when the desvenlafaxine dose was 100 mg/day (a 25% increase in Cmax and 17% in AUC) 1.

Common questions

Can I take Amitriptyline and Desvenlafaxine together?

Taking amitriptyline with desvenlafaxine can raise amitriptyline levels and increase the risk of serotonin syndrome, so watch for symptoms like fever, fast heartbeat, and confusion. Your care team can manage this by tailoring your dose and monitoring you closely, so keep both as prescribed and report any warning signs. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Amitriptyline and Desvenlafaxine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Amitriptyline and Desvenlafaxine interaction managed?

Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination can be managed with the right dosing and monitoring. At usual desvenlafaxine doses (100 mg/day or less), amitriptyline typically does not need a dose change. At very high desvenlafaxine doses, your team may lower the amitriptyline dose and restore it later; they will individualize this. Your care… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

From our Q&A

Real reader questions about these medications, each personally answered by our pharmacist:

Questions for your pharmacist

  • Does my dose of Amitriptyline or Desvenlafaxine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: PRISTIQ(R) oral extended-release tablets, desvenlafaxine oral extended-release tablets. Wyeth Pharmaceuticals Inc (per FDA), Philadelphia, PA, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.